Patheon IncTSX: PTI

Merck & Co., Inc. Selects Patheon as Strategic Supplier

· Issued by Patheon Inc via CNW
TORONTO, Jan. 26 /CNW/ - Patheon Inc. (TSX: PTI) today announced that
Patheon has entered into a five-year master supply agreement with Merck & Co.,
Inc. (NYSE: MRK) to provide commercial manufacturing and pharmaceutical
development services to Merck, and that Merck has selected Patheon as one of
Merck's strategic partners for commercial manufacturing and pharmaceutical
development services.
The new master supply agreement is designed to facilitate the inclusion
of additional products and projects as Merck implements a new strategic plan,
which includes leveraging external capabilities and capacity. As a strategic
partner for Merck, Patheon will be provided the opportunity to participate in
future commercial manufacturing and appropriate product development projects.
"As Merck implements its new supply strategy, we look forward to working
with top-tier manufacturers, such as Patheon, to more effectively leverage
external manufacturing across a broad spectrum of capabilities," noted Willie
A. Deese, President, Merck Manufacturing Division, Merck & Co., Inc.
Merck has awarded Patheon three new projects as the first step in this
new relationship. One project is a late-stage development product for
Patheon's Caguas, Puerto Rico, facility. A second project involves activity at
Patheon's Cincinnati facility and a third project involves activity at
Patheon's Toronto Regional Operations in Mississauga, Canada. These projects
are expected to generate commercial revenues for Patheon in fiscal year 2007,
if regulatory approvals for these products are obtained within the planned
timelines. Patheon is currently providing development services in connection
with these projects.
Patheon's subsidiary, MOVA Pharmaceutical Corporation, and Merck have had
a long relationship that commenced with a ten-year supply contract in December
1987 and that continues to this day.
"We are very pleased that we are building on the strong foundation
established by MOVA and look forward to the opportunity to deepen our
relationship with Merck as a strategic supplier of commercial manufacturing
and development services in the future," commented Robert Tedford, Chief
Executive Officer, Patheon Inc. "This agreement recognizes the value of
Patheon's full-service, value-added approach in satisfying our clients'
needs."

About Patheon

Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug
development and manufacturing services to the international pharmaceutical
industry. Patheon operates a network of 14 facilities in the United States,
Canada and Europe, employing more than 5,900 people and serving a client base
of 180 pharmaceutical and biotechnology companies.

Forward-Looking Statement

This news release contains forward-looking statements with respect to
Patheon, including its business operations and strategy and financial
performance and condition. Although management believes that the expectations
reflected in such forward-looking statements are reasonable, such statements
involve risks and uncertainties. Actual results may differ materially from
those expressed or implied by such forward-looking statements. Factors that
could cause actual results to differ materially from expectations include, but
are not limited to, currency fluctuations, the level of outsourcing services
required by the pharmaceutical companies (and in particular our clients), the
impact of changes in pharmaceutical development and manufacturing regulations
and general economic and market factors (including inflation and changes in
laws) and other factors discussed in materials filed with applicable
securities regulatory authorities from time to time.

About Merck

Merck & Co., Inc. is a global research-driven pharmaceutical company
dedicated to putting patients first. Established in 1891, Merck currently
discovers, develops, manufactures and markets vaccines and medicines to
address unmet medical needs. The Company devotes extensive efforts to increase
access to medicines through far-reaching programs that not only donate Merck
medicines but help deliver them to the people who need them. Merck also
publishes unbiased health information as a not-for-profit service. For more
information, visit www.merck.com.

Forward-Looking Statement

This press release, including the financial information that follows,
contains "forward-looking statements" as that term is defined in the Private
Securities Litigation Reform Act of 1995. These statements are based on
management's current expectations and involve risks and uncertainties, which
may cause results to differ materially from those set forth in the statements.
The forward-looking statements may include statements regarding product
development, product potential or financial performance. No forward-looking
statement can be guaranteed, and actual results may differ materially from
those projected. Merck undertakes no obligation to publicly update any forward-
looking statement, whether as a result of new information, future events, or
otherwise. Forward-looking statements in this press release should be
evaluated together with the many uncertainties that affect Merck's business,
particularly those mentioned in the cautionary statements in Item 1 of Merck's
Form 10-K for the year ended Dec. 31, 2004, and in its periodic reports on
Form 10-Q and Form 8-K, which the Company incorporates by reference.

%SEDAR: 00001700E

Patheon Inc on 6ix

Earlier from Patheon

Later from Patheon

All Patheon news releases